Impact of Microbiota Depletion by Antibiotics on SARS-CoV-2 Infection of K18-hACE2 Mice.
COVID-19
SARS-CoV-2
colon
gut-to-lung axis
intestinal microbiota
respiratory infection
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
18 08 2022
18 08 2022
Historique:
received:
16
07
2022
revised:
12
08
2022
accepted:
13
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Clinical and experimental data indicate that severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection is associated with significant changes in the composition and function of intestinal microbiota. However, the relevance of these effects for SARS-CoV-2 pathophysiology is unknown. In this study, we analyzed the impact of microbiota depletion after antibiotic treatment on the clinical and immunological responses of K18-hACE2 mice to SARS-CoV-2 infection. Mice were treated with a combination of antibiotics (kanamycin, gentamicin, metronidazole, vancomycin, and colistin, Abx) for 3 days, and 24 h later, they were infected with SARS-CoV-2 B lineage. Here, we show that more than 80% of mice succumbed to infection by day 11 post-infection. Treatment with Abx had no impact on mortality. However, Abx-treated mice presented better clinical symptoms, with similar weight loss between infected-treated and non-treated groups. We observed no differences in lung and colon histopathological scores or lung, colon, heart, brain and kidney viral load between groups on day 5 of infection. Despite some minor differences in the expression of antiviral and inflammatory markers in the lungs and colon, no robust change was observed in Abx-treated mice. Together, these findings indicate that microbiota depletion has no impact on SARS-CoV-2 infection in mice.
Identifiants
pubmed: 36010648
pii: cells11162572
doi: 10.3390/cells11162572
pmc: PMC9406363
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
K-18 conjugate
0
gamma-Globulins
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Melphalan
Q41OR9510P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS Pathog. 2017 Aug 17;13(8):e1006513
pubmed: 28817707
Front Immunol. 2022 Jan 20;13:773261
pubmed: 35126390
Viruses. 2021 Jan 19;13(1):
pubmed: 33477869
Exp Mol Med. 2020 Jul;52(7):1128-1139
pubmed: 32681029
Sci Rep. 2021 Mar 26;11(1):7008
pubmed: 33772084
Gut Microbes. 2021 Jan-Dec;13(1):1-19
pubmed: 33685349
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Gut. 2021 Apr;70(4):698-706
pubmed: 33431578
Mucosal Immunol. 2019 Jul;12(4):843-850
pubmed: 30976087
Cell Rep. 2019 Apr 16;27(3):750-761.e7
pubmed: 30995474
Mucosal Immunol. 2021 Nov;14(6):1381-1392
pubmed: 34420043
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
Crit Care. 2020 Oct 15;24(1):611
pubmed: 33076936
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Biotechnol. 2017 Nov 10;261:169-176
pubmed: 28648396
Nucleic Acids Res. 2014 Jan;42(Database issue):D643-8
pubmed: 24293649
PLoS Pathog. 2021 Aug 9;17(8):e1009427
pubmed: 34370799
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
EBioMedicine. 2022 Mar;77:103891
pubmed: 35220042
Am J Trop Med Hyg. 2020 Sep;103(3):1215-1219
pubmed: 32723427
Microbiome. 2017 Mar 3;5(1):27
pubmed: 28253908
mSystems. 2018 Apr 17;3(3):
pubmed: 29719869
Gut Microbes. 2011 May-Jun;2(3):145-58
pubmed: 21804357
Respir Res. 2014 Apr 16;15:46
pubmed: 24735374
Gut Microbes. 2021 Jan-Dec;13(1):1-9
pubmed: 33550892
Cell. 2016 Nov 3;167(4):1125-1136.e8
pubmed: 27814509
Front Immunol. 2020 Sep 29;11:568636
pubmed: 33133080
Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9
pubmed: 21402903
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
Front Immunol. 2022 Jan 26;12:828887
pubmed: 35154087
Sci Immunol. 2022 Jan 28;7(67):eabl9929
pubmed: 34812647
BMC Infect Dis. 2021 Nov 8;21(1):1144
pubmed: 34749645
Arterioscler Thromb Vasc Biol. 2021 Nov;41(11):2773-2785
pubmed: 34496633
Gut. 2020 Jun;69(6):997-1001
pubmed: 32241899
Lancet Respir Med. 2021 Feb;9(2):117
pubmed: 33484632
Front Immunol. 2022 Feb 28;13:784486
pubmed: 35296081
Immunity. 2018 May 15;48(5):992-1005.e8
pubmed: 29768180
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Nat Commun. 2022 Nov 1;13(1):5926
pubmed: 36319618
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
PLoS Comput Biol. 2021 Nov 8;17(11):e1009581
pubmed: 34748542
Cell. 2016 Nov 17;167(5):1339-1353.e21
pubmed: 27863247
Gut Microbes. 2022 Jan-Dec;14(1):2018900
pubmed: 34965194
Appl Environ Microbiol. 2005 Dec;71(12):8228-35
pubmed: 16332807
J Virol. 2022 Jan 12;96(1):e0096421
pubmed: 34668775
Mucosal Immunol. 2021 Mar;14(2):296-304
pubmed: 33500564
Vaccines (Basel). 2021 May 06;9(5):
pubmed: 34066475
Emerg Microbes Infect. 2020 Dec;9(1):2169-2179
pubmed: 32969768
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
Eur Respir J. 2021 Jul 8;58(1):
pubmed: 33361100
Nat Commun. 2019 Jul 22;10(1):3273
pubmed: 31332169
Cell Biosci. 2020 Mar 16;10:40
pubmed: 32190290
Front Microbiol. 2021 Feb 02;11:586476
pubmed: 33603716
Cell Rep. 2018 Mar 27;22(13):3440-3453.e6
pubmed: 29590614
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
Microbiol Spectr. 2021 Sep 3;9(1):e0053621
pubmed: 34378965
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Am J Surg Pathol. 2022 Jan 1;46(1):89-96
pubmed: 34081038
Front Immunol. 2021 Jul 14;12:708149
pubmed: 34335624
PLoS Pathog. 2021 Jan 19;17(1):e1009195
pubmed: 33465158
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Front Cell Infect Microbiol. 2021 Nov 17;11:747816
pubmed: 34869058
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773